

Special Issue

Recent Advances in Vaccine Adjuvants and Formulation

Message from the Guest Editors

Vaccines are essential in eradicating or controlling many infectious diseases. However, there is still an urgent need for vaccines that fully stimulate cellular, long-lasting immunity, and even mucosal immunity. In addition, due to the uniqueness of each disease and the specific types of immune responses to be modulated, various kinds of novel adjuvants are needed to induce optimal immune responses against a particular disease. In the last two decades, compound adjuvants, especially in different formulations based on traditional aluminum adjuvant sources, have gained much interest in the generation of new vaccines since they can integrate all components and synergistically enhance the advantages of innate and adaptive immune responses. Therefore, on this topic, we invite the submission of original and review articles which focus on novel vaccine adjuvants and attain their nature, formulation, delivery, mode of action, beneficial and adverse effects, quality control, and induced immune responses to accomplish efficient and long-lasting protection against infectious diseases.

Assistant

Guest Editors

Dr. Aihua Zhao

1. Division of Tuberculosis Vaccine and Allergen Products, Institute of Biological Product Control, National Institutes for Food and Drug Control, Beijing 102629, China
2. Key Laboratory for Quality Research and Evaluation of Biological Products, National Medical Products Administration (NMPA), Beijing 102629, China

Dr. Junli Li

1. Division of Tuberculosis Vaccine and Allergen Products, Institute of Biological Product Control, National Institutes for Food and Drug Control, Beijing 102629, China
2. Key Laboratory for Quality Research and Evaluation of Biological Products, National Medical Products Administration (NMPA), Beijing 102629, China

Deadline for manuscript submissions

closed (30 April 2025)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/183469

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).